Sema4 Holdings Corp. (SMFR)

NASDAQ: SMFR · IEX Real-Time Price · USD
2.30
+0.13 (5.99%)
Aug 12, 2022 11:26 AM EDT - Market open
5.99%
Market Cap 867.67M
Revenue (ttm) 201.79M
Net Income (ttm) -131.29M
Shares Out 377.25M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 505,440
Open 2.17
Previous Close 2.17
Day's Range 2.16 - 2.31
52-Week Range 1.11 - 11.90
Beta n/a
Analysts Buy
Price Target 4.34 (+88.7%)
Earnings Date Aug 15, 2022

About SMFR

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances preci... [Read more...]

Industry Health Information Services
Founded 2017
Employees 1,200
Stock Exchange NASDAQ
Ticker Symbol SMFR
Full Company Profile

Financial Performance

In 2021, Sema4 Holdings's revenue was $212.20 million, an increase of 18.33% compared to the previous year's $179.32 million. Losses were -$245.39 million, 1.68% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SMFR stock is "Buy." The 12-month stock price forecast is 4.34, which is an increase of 88.70% from the latest price.

Price Target
$4.34
(88.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sema4 Holdings Corp. (SMFR) Moves to Buy: Rationale Behind the Upgrade

Sema4 Holdings Corp. (SMFR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sema4 Announces Chief Financial Officer Transition Plan

Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer

Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area

The wide-ranging Avera/Sema4 Oncology and Analytics Protocol (ASAP) study is expected to enable precision oncology care for thousands of patients The wide-ranging Avera/Sema4 Oncology and Analytics Prot...

5 Stocks Under $2 Insiders Are Aggressively Buying

US crude oil futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: AVCTBODYOTRKVHC

Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the compe...

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth ...

Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S.

Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the ...

Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year

SEMA4 HOLDINGS INVESTOR ALERT - Kuznicki Law PLLC Investigates Sema4 Holdings Corp. - SMFR

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of GeneDx, Inc. to Sema4 Holdings Corp. (“the Company”) (NasdaqGS: SMFR). Under the terms of the proposed transact...

SEMA4 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Sema4 ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GeneDx, Inc. to Se...

INVESTIGATION ALERT: Kaskela Law LLC Announces Stockholder Investigation of Sema4 Holdings Corp. (SMFR) in Connection...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2022) - Investor protection firm Kaskela Law LLC announces that is investigating the Board of Directors of Sema4 Holdings Corp. ("Sema4") (NASD...

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March ...

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the f...

Sema4 to Participate at Two Upcoming Investor Conferences in February

STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at...

Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities

30-year industry veteran, Jerry Conway, joins Sema4 as Senior Vice President of Market Access to lead the team 30-year industry veteran, Jerry Conway, joins Sema4 as Senior Vice President of Market Acce...

Sema4 (SMFR) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Sema4 Holdings ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Sema4 Holdings Corp. (NASDAQ: SMFR) and GeneDx, Inc. is fair to Sema4 shareholders....

Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition

Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623 million. Sema4 will acquire GeneDx for an upfront pay...

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Business combination projected to deliver $350 million in pro forma 2022 revenue

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

Fourth quarter and fiscal year results are expected to exceed the high end of guidance for both total revenue and resulted test volume Fourth quarter and fiscal year results are expected to exceed the h...

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and Chief Ex...

Sema4, Excluding COVID-19, Posts 36% Increase In Test Volume In Q3

Sema4 Holdings Corp (NASDAQ: SMFR) reported Q3 revenues of $43.2 million, +12% Y/Y, beating the consensus of $42.68 million. Diagnostic test revenue was $41.4 million, up 7%, while other revenue more th...

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

36% increase in test volume (excluding COVID-19 tests) compared to the same period last year

Sema4 to Participate at Three Upcoming Investor Conferences in November

STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at...

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the t...

Sema4 to Participate at Two Upcoming Investor Conferences in September

STAMFORD, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, Ph.D., Founder and Chief ...

Why Sema4 Holdings Stock Is Sinking Today

Investors weren't happy with the company's Q2 update.